The global Pulmonary Arterial Hypertension market size is estimated at 11.96 billion USD with a CAGR of 7.8% during the forecasted period from 2021-2028.
TABLE OF CONTENTS Chapter 1 Introduction 1.1 Executive Summary 1.2 Market Definition 1.3 Market Scope Chapter 2 Research Methodology 2.1 Primary Research 2.2 Research Methodology 2.3 Assumptions & Exclusions 2.4 Secondary Data Sources Chapter 3 Market Overview 3.1 Report Segmentation & Scope 3.2 Key Market Trends 3.2.1 Drivers 3.2.2 Restraints 3.2.3 Opportunities 3.3 Porter’s Five Forces Analysis 3.4 Market Share Analysis Chapter 4 Global Pulmonary Arterial Hypertension Market by Drug Class: Market Size and Forecast, 2018 – 2026 4.1 Introduction 4.1.1 Market Size and Forecast 4.2 Endothelin Receptor Antagonists (ERAs) 4.2.1 Market Size and Forecast 4.3 Prostacyclin and Prostacyclin Analogs 4.3.1 Market Size and Forecast 4.4 Phosphodiesterase-5 (PDE-5) Inhibitors 4.4.1 Market Size and Forecast 4.5 Soluble Guanylate Cyclase (sGC) Stimulators 4.5.1 Market Size and Forecast Chapter 5 Global Pulmonary Arterial Hypertension Market by Application: Market Size and Forecast, 2018 – 2026 5.1 Introduction 5.1.1 Market Size and Forecast 5.2 Hospitals 5.2.1 Market Size and Forecast 5.3 Clinics 5.3.1 Market Size and Forecast 5.4 Other Applications 5.4.1 Market Size and Forecast Chapter 6 Global Pulmonary Arterial Hypertension Market by Geography: Market Size and Forecast, 2018 – 2026 6.1 Introduction 6.1.1 Market Size and Forecast 6.2 North America 6.2.1 North America Market Size & Forecast, By Country 6.2.2 North America Market Size & Forecast, By Drug Class 6.2.3 North America Market Size & Forecast, By Application 6.2.4 The U.S. 6.2.4.1 Market Size and Forecast 6.2.5 Canada 6.2.5.1 Market Size and Forecast 6.2.6 Mexico 6.2.6.1 Market Size and Forecast 6.3 Europe 6.3.1 Europe Market Size and Forecast, By Country 6.3.2 Europe Market Size and Forecast, By Drug Class 6.3.3 Europe Market Size and Forecast, By Application 6.3.4 UK 6.3.4.1 Market Size and Forecast 6.3.5 Germany 6.3.5.1 Market Size and Forecast 6.3.6 France 6.3.6.1 Market Size and Forecast 6.3.7 Italy 6.3.7.1 Market Size and Forecast 6.3.8 Spain 6.3.8.1 Market Size and Forecast 6.3.9 Rest of Europe 6.3.9.1 Market Size and Forecast 6.4 Asia-Pacific 6.4.1 Asia-Pacific Market Size and Forecast, By Country 6.4.2 Asia-Pacific Market Size and Forecast, By Drug Class 6.4.3 Asia-Pacific Market Size and Forecast, By Application 6.4.4 India 6.4.4.1 Market Size and Forecast 6.4.5 China 6.4.5.1 Market Size and Forecast 6.4.6 Australia 6.4.6.1 Market Size and Forecast 6.4.7 Japan 6.4.7.1 Market Size and Forecast 6.4.8 South Korea 6.4.8.1 Market Size and Forecast 6.4.9 Rest of Asia-Pacific 6.4.9.1 Market Size and Forecast 6.5 South America 6.5.1 South America Market Size and Forecast, By Country 6.5.2 South America Market Size and Forecast, By Drug Class 6.5.3 South America Market Size and Forecast, By Application 6.5.4 Brazil 6.5.4.1 Market Size and Forecast 6.5.5 Rest of South America 6.5.5.1 Market Size and Forecast 6.6 RoW 6.6.1 RoW Market Size and Forecast, By Country 6.6.2 RoW Market Size and Forecast, By Drug Class 6.6.3 RoW Market Size and Forecast, By Application 6.6.4 RoW Market Size and Forecast, By End-User 6.6.5 Middle East 6.6.5.1 Market Size and Forecast 6.6.6 Africa 6.6.6.1 Market Size and Forecast Chapter 7 Company Profiles 7.1 Actelion Pharmaceuticals, Ltd. 7.2 Bayer HealthCare 7.3 Gilead Sciences, Inc. 7.4 GlaxoSmithKline Plc. 7.5 Novartis International AG 7.6 Pfizer, Inc. 7.7 United Therapeutics Corporation
(US)
